Abstract
effects CIFN had to be reduced in 13% and discontinued in 7% of patients. 98% of genotype 2/3 patients and 67% of genotype 1 patients have so far responded. CIFN daily dosing/induction therapy thus shows significant response rates comparable to PEG-IFN/ribavirin combination especially in genotype 1, high viral load patients. The further follow-up will show the additional effect of ribavirin and whether the initial high response rates will translate into corresponding sustained response rates. severity of liver disease, viral load, ALT, and creatinine level, in HCV positive RT group. Conelnsiom Both HCV+ and HCVRT patients had higher number of active T cells and natural killer cells in comparison to controls. Decreased number of B cell in RT patients may result from immunosuppressive treatment. Increase in CD8 number in HCV+RT patients may be due to the absence of CD4 Thl response on CD8 regulation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
